Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 3/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11441541 | 0.66 | ADCY5 (0.52) | HTR2CMAPT | |
| SCHEMBL8355159 | 0.64 | — | — | |
| SCHEMBL2680514 | 0.63 | — | — | |
| SCHEMBL2353396 | 0.62 | — | — | |
| SCHEMBL9617164 | 0.62 | — | — | |
| SCHEMBL1101108 | 0.62 | — | — | |
| SCHEMBL7740398 | 0.61 | — | — | |
| SCHEMBL5202273 | 0.60 | MAPT (0.32) | GABRA1GABRG2GABRB3HTR2CMAPT | |
| SCHEMBL1022167 | 0.60 | — | — | |
| SCHEMBL5879404 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101068782-A | Method for synthesizing 4- (3-sulfonylphenyl) -piperidines | NEUROSEARCH SWEDEN AB (SE) | 2007-11-07 | — | — | CN | disclosed |
| US-20070238878-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-10-11 | — | — | US | disclosed |
| US-20070238878-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-10-11 | — | — | US | disclosed |
| EP-1807394-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | Neurosearch Sweden AB (SE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1807394-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | Neurosearch Sweden AB (SE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006040156-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | NEUROSEARCH SWEDEN AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040156-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | NEUROSEARCH SWEDEN AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238878-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES | CAT, SQOR, CYP2B6 | GABRA1 2421/4885GABRG2 1564/4885GABRB3 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.